NCT07259317Phase 2Recruiting

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Study sponsor: Corcept Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-09Estimated
Enrollment · participants80Estimated
Source updated2026-09-25Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression-Free Survival (PFS). After: Measure: Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1) Measure: Number of Patients with 1 or More Adverse Events (AEs) Leading to Study Drug Discontinuations or Dose Modifications (Part 1) Measure: Progression-Free Survival (PFS) (Part 2).

Planned enrollment increased by 20 participants

Before: 60 participants (planned). After: 80 participants (planned).

Primary completion date changed

Before: Jul 2027. After: Sep 2027.

Check registry source

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source